Suchergebnisse - "Ohashi, Kadoaki"

PubPharm (147)

1

Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop : Results from LC-SCRUM-Asia

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Okahisa, M. | Udagawa, H. | Matsumoto, S. | +24

2

A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing

enthalten in: Internal medicine (Tokyo, Japan) | 2024

von Matsuura, H. | Makimoto, G. | Oda, N. | +9

3

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer : CS-Lung-003 prospective observational registry study

enthalten in: Journal of cancer research and clinical oncology | 2024

von Kuribayashi, T. | Ohashi, K. | Nishii, K. | +19

4

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study

enthalten in: Journal of cancer research and clinical oncology | 2024

von Kuribayashi, T. | Ohashi, K. | Nishii, K. | +19

5

Cutaneous toxicity with subepidermal blisters and dyskeratosis following administration of pemetrexed in a patient with nivolumab-induced psoriasis and linear IgA bullous dermatosis

enthalten in: The Journal of dermatology | 2024

von Yokomizo, S. | Miyake, T. | Kawakami, Y. | +4

6

Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies

enthalten in: International journal of cancer | 2024

von Kemmotsu, N. | Ninomiya, K. | Kunimasa, K. | +15

7

Survival Mechanisms of Drug Tolerant Persister Cancer Cells against Targeted Anticancer Drugs

enthalten in: Gan to kagaku ryoho. Cancer & chemotherapy | 2023

von Taoka, M. | Makimoto, G. | Ohashi, K.

8

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2023

von Ahn, M. | Cho, B. | Felip, E. | +85

9

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC

enthalten in: The New England journal of medicine | 2023

von Zhou, C. | Solomon, B. | Loong, H. | +122

CommentIn: Cancer Discov. 2023 Dec 12;13(12):OF8. - PMID 37874126

10

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer

enthalten in: Cancer science | 2023

von Ando, C. | Ichihara, E. | Nishi, T. | +18

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[15]